Latest Healthcare in India Stories
CALGARY, Oct. 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") announced today that it has made an investment in British Canadian Biosciences Corp. (BCBC), a privately held biotechnology company specializing in the development of peptides for the treatment of a variety of conditions, including cancer. Oncolytics has purchased all of the convertible preferred shares of BCBC in exchange for 200,000 common shares of Oncolytics. If converted to common...
CALGARY, Oct. 7 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 17th Annual BioPartnering Europe conference in London, U.K. on Monday, October 12 at 10:15 a.m. The conference is taking place at the Queen Elizabeth II Conference Centre from October 11-13, 2009. About Oncolytics Biotech Inc. Oncolytics is a Calgary-based biotechnology company focused on the development...
CALGARY, Oct. 1 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), will host a conference call and webcast on Friday, October 2, 2009 at 6:30 a.m. MT (8:30 a.m. ET) to update investors on the Company's Phase 3 program for REOLYSIN(R). To access the conference call by telephone, dial 1-416-644-3426 or 1-800-732-1073. A live audio webcast will also be available at the following link:...
PLANO, Texas and NEW DELHI, Sept. 18 /PRNewswire-FirstCall/ -- Max Healthcare (MHC) (www.maxhealthcare.in) and Perot Systems Corporation (NYSE: PER) (www.perotsystems.com) today announced a 10-year agreement in which Perot Systems will provide IT outsourcing (ITO) and electronic health records (EHR) implementation for MHC. This agreement marks Perot Systems' first full ITO in the Indian healthcare industry as well as the company's first India-based healthcare client. In this more than Rs....
IRVINE, Calif., Sept. 10 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it will present at the NewsMakers in the Biotech Industry Conference at 11:30 a.m. Eastern Time on September 16, 2009, at the Millennium Broadway Hotel in New York, NY. ISTA's Chief Financial Officer and Vice President of Corporate Development Lauren Silvernail will provide an update on the Company's commercial and clinical progress. To access the live audio broadcast, or the...
MUMBAI, India, September 9 /PRNewswire/ -- - Annual India Excellence in Healthcare Awards to Celebrate Best in the Industry Frost & Sullivan, for the first time, hosted '2009 India excellence in Healthcare Awards' at Mumbai. The Event attended by the creme de la creme of the healthcare industry spotlighted world-class companies that have performed par excellence and demonstrated best practices. Recognizing the best in class, the event was held to honor the country's...
CALGARY, Sept. 8 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the Rodman Renshaw 11th Annual Healthcare Conference on Thursday, September 10, 2009 at 10:00 a.m. ET. The event will be held at the New York Palace Hotel from September 9 to 11, 2009. A live audio webcast of the presentation will be available at: http://www.wsw.com/webcast/rrshq15/oncy or on the company's website at www.oncolyticsbiotech.com. It...
SAN FRANCISCO, Sept. 1 /PRNewswire/ -- Just as biotech was "hot" in July it was a different story in August as the Burrill Biotech Select Index suffered from the summer "blahs" and posted a lackluster performance to close down 1.1 percent. The broader markets, on the other hand, continued their upward swing with the Dow closing the month up a healthy 3.5 percent and the Nasdaq closing up 1.5 percent. Investors were, however, reminded on the last day of the trading month, that despite...
BALTIMORE, Md., Aug. 27 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced its financial results for the fiscal year ended April 30, 2009. Full details of the Company's financial results are available in the Company's Form 10-K available at www.championsbiotechnology.com. For the fiscal year ended April 30,...
JERUSALEM, August 25 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, today announced that it is the recipient of the 2009 Frost & Sullivan European Oral Drug Delivery Technology Innovation Award. Oramed Pharmaceuticals is developing a platform technology to create oral delivery systems for drugs and vaccines delivered via injection. Oramed focuses on the treatment of diabetes through its...
